Immune Response Affecting Drug Patents (Class 514/885)
-
Patent number: 5965122Abstract: Mammalian Interleukin-7 proteins (IL-7s)g DNAs and expression vectors encoding mammalian IL-7s, end processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.Type: GrantFiled: June 9, 1997Date of Patent: October 12, 1999Assignee: SANOFIInventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki
-
Patent number: 5962406Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.Type: GrantFiled: June 7, 1995Date of Patent: October 5, 1999Assignee: Immunex CorporationInventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson, Arvia E. Morris, Jeffrey T. McGrew
-
Patent number: 5962634Abstract: The present invention relates to methods for modulating interaction between IgE and Fc.epsilon.R1. The present invention also relates to compounds that modulate IgE binding to Fc.epsilon.R1.Type: GrantFiled: April 30, 1997Date of Patent: October 5, 1999Assignees: Thomas Jefferson University, King's CollegeInventors: Bradford A. Jameson, Brian J. Sutton, James M. McDonnell, Hannah J. Gould, Robert Korngold, Andrew J. Beavil
-
Patent number: 5958432Abstract: Cosmetic/pharmaceutical compositions, well suited for the treatment of a variety of mammalian disorders of, for example, the skin, hair and/or mucous membranes, a manifestation of which is an excess in the synthesis and/or in the release of substance P, e.g., for the treatment of cutaneous disorders and sensitive skin, comprise an effective substance P antagonist amount of at least one .beta.-adrenergic agonist, e.g., salbutamol, in a cosmetically/pharmaceutically acceptable medium therefor.Type: GrantFiled: October 23, 1996Date of Patent: September 28, 1999Assignee: Societe L'Oreal S.A.Inventors: Lionel Breton, Olivier de Lacharriere, Jacques Leclaire
-
Patent number: 5958416Abstract: The invention provides for peptides and methods of using peptides to block or inhibit a pathogenic autoimmune response to central nervous system components. One class of peptides are antigens derived from mycobacterial heat shock proteins and may immunologically cross-react with or are homologous to myelin components. The peptides can also be derived from myelin components such as 2',3' cyclic nucleotide phosphodiesterase and immunologically cross-react with and/or are homologous to mycobacterial heat shock proteins. A method of the invention involves administering a pharmaceutical composition including at least one peptide to an animal in an amount effective to block or inhibit a pathogenic autoimmune response to central nervous system components. The peptides are useful for the prevention, and treatment of autoimmune inflammatory central nervous system disease.Type: GrantFiled: May 23, 1995Date of Patent: September 28, 1999Assignees: Regents of the University of Minnesota, McGill UniversityInventors: Gary Birnbaum, Linda A. Kotilinek, Peter Erich Braun
-
Patent number: 5958401Abstract: Provided by the present invention are methods of treating psoriasis using IL-11.Type: GrantFiled: December 10, 1997Date of Patent: September 28, 1999Assignee: Genetics Institute, Inc.Inventors: James Keith, Paul Schendel
-
Covalent lipid-phosphono-carboxylic acid conjugates and application thereof as antiviral medicaments
Patent number: 5955452Abstract: The present invention concerns new lipid derivatives of phosphonocarboxylic acids of the general formula I, ##STR1## in which the meaning of the symbols is elucidated in the description, tautomers thereof and their physiologically tolerated salts of inorganic and organic bases as well as processes for the production thereof and pharmaceutical agents containing these compounds.Type: GrantFiled: August 26, 1998Date of Patent: September 21, 1999Assignee: Roche Diagnostics GmbHInventors: Harald Zilch, Dieter Herrmann, Hans-George Opitz, Gerd Zimmermann, Edgar Voss -
Patent number: 5951971Abstract: An ophthalmic composition particularly in the form of eye-drops suitable for the treatment of diseases of the eye and surrounding areas. The composition contains a cyclosporin and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers and polyoxyethylene alkyl ethers, or mixtures thereof.Type: GrantFiled: December 17, 1996Date of Patent: September 14, 1999Assignee: Novartis AGInventors: Yoichi Kawashima, Mitsuaki Kuwano
-
Patent number: 5951973Abstract: A method of treating rheumatoid arthritis comprising administering human Interleukin-4 (IL-4) to an individual afflicted with the disease. The IL-4 is administered with a pharmaceutically acceptable carrier in a dose ranging from 1 .mu.g to 100 mg.Type: GrantFiled: June 6, 1995Date of Patent: September 14, 1999Assignee: Schering CorporationInventors: Frank Lee, Takashi Yokota, Ken-ichi Arai, Timothy Mosmann, Donna Rennick
-
Patent number: 5952296Abstract: Methods of using relaxin (RLX), a peptide hormone of the insulin family, which has been found to produce effects on the walls of blood vessels, on blood clotting and on blood lipids and electrolytes, per se, and through the stimulation of the synthesis and release of the two powerful substances: nitric oxide (NO) and atrial natriuretic peptide (ANP), are contemplated whereby RLX is administered to a patient for increasing blood flow, producing dilation of the arteries, influencing blood clotting and fibrinolysis, reducing blood lipids, inducing reduction of blood osmolarity and sodium concentration, and through NO for inhibiting release of histamine from mast cells. RLX is accordingly used as a therapeutic agent in methods for treating arteriosclerosis and vascular diseases, ischemia and thrombosis, hypertension and pregnancy's gestosis, and other diseases, or allergic and inflammatory disorders as dysfunctions in fluid and electrolyte balance.Type: GrantFiled: March 23, 1995Date of Patent: September 14, 1999Inventor: Mario Bigazzi
-
Patent number: 5948402Abstract: Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, and allergic disorders such as rhinitis, conjunctivitis, and urticaria.Type: GrantFiled: July 15, 1997Date of Patent: September 7, 1999Assignee: Genetics Institute, Inc.Inventors: James Keith, Paul Schendel
-
Patent number: 5942231Abstract: A method of treating a patient suffering from allergic diseases, comprises administering to said patient an effective amount of a pharmaceutical composition in dosage unit form comprising a dry powder of guava leaves.Type: GrantFiled: June 18, 1996Date of Patent: August 24, 1999Assignee: O.S. Industry Co., Ltd.Inventors: Sadao Hamada, Susumu Kitanaka
-
Patent number: 5942229Abstract: Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary humoral immune responses can be suppressed and suppression is prolonged.Type: GrantFiled: June 7, 1995Date of Patent: August 24, 1999Assignee: Trustees of Dartmouth CollegeInventors: Randolph J. Noelle, Teresa M. Foy
-
Patent number: 5939069Abstract: The subject invention concerns novel materials and methods for the treatment and/or prevention of autoimmune disease. In a specific embodiment, elevated production of prostaglandin synthase-2 (PGS-2) is correlated with autoimmune dysfunction.Type: GrantFiled: August 23, 1996Date of Patent: August 17, 1999Assignee: University of FloridaInventor: Michael Clare-Salzler
-
Patent number: 5939526Abstract: The invention describes the RAGE tumor rejection antigen precursor family, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a RAGE tumor rejection antigen precursor.Type: GrantFiled: September 20, 1995Date of Patent: August 17, 1999Assignee: Ludwig Institute for Cancer ResearchInventors: Beatrice Gaugler, Benoit Van den Eynde, Peter Schrier, Nathalie Brouwenstijn, Thierry Boon-Falleur
-
Patent number: 5939394Abstract: The present invention relates to compositions and methods for the prevention and/or treatment of allergic, autoimmune, septic shock or infectious diseases using magnesium gluconate alone or in combination with one or more antioxidants or an antiinflammatory agent. The invention also relates to the inhibition of production of inappropriate levels of lipid mediators and cytokines.Type: GrantFiled: April 23, 1997Date of Patent: August 17, 1999Assignee: Fleming & CompanyInventors: Thomas E. Fleming, Herbert C. Mansmann, Jr.
-
Patent number: 5935929Abstract: A method for the treatment and prevention of immune disorders and fibrosis associated disorders is disclosed. The method involves administering interleukin-9 in an effective amount to the subject. Among the conditions treatable are thyroiditis, autoimmune diabetes and silicosis.Type: GrantFiled: September 8, 1997Date of Patent: August 10, 1999Assignee: Ludwig Institute for Cancer ResearchInventors: Jean-Christophe Renauld, Mary-Christine Many, Francois Huaux, Dominique Lison
-
Patent number: 5935577Abstract: A combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease.Type: GrantFiled: January 23, 1998Date of Patent: August 10, 1999Assignee: Autoimmune Inc.Inventors: Howard L. Weiner, Ahmad Al-Sabbagh, Patricia A. Nelson
-
Patent number: 5932214Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.Type: GrantFiled: October 15, 1997Date of Patent: August 3, 1999Assignee: Biogen, Inc.Inventors: Roy R. Lobb, Linda C. Burkly
-
Patent number: 5932595Abstract: The present invention relates to compounds of Formula I: ##STR1## that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.Type: GrantFiled: December 18, 1996Date of Patent: August 3, 1999Assignees: Syntex (U.S.A.) Inc., Agouron Pharmaceuticals, Inc.Inventors: Steven Lee Bender, Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Lawrence Emerson Fisher, Robert Than Hendricks, Keshab Sarma
-
Patent number: 5928636Abstract: The present invention provides a combination of IL-12 and IFN.alpha. together with a pharmaceutically acceptable carrier useful for treatment and prophylaxis of infectious diseases, preferably chronic infectious diseases and more preferably viral infections, e.g. HSV, HIV, Hepatitis B, Hepatitis C, papilloma etc., bacterial infections, e.g. tuberculosis, salmonellosis, listeriosis, etc., and parasite infections, e.g. malaria, leishmaniasis, and schistosomiasis. These compositions are characterized by the synergistic interaction of IL-12 and IFN.alpha.. The present invention also provides the use of the above combination for the treatment and prophylaxis of infectious diseases.Type: GrantFiled: April 30, 1997Date of Patent: July 27, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Gottfried Alber, Jacqueline Anne Carr, Frank Albert Mattner, Michael John Mulqueen, Kathrin Palmer, Jane Andre Louise Rogerson
-
Patent number: 5925352Abstract: An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.Type: GrantFiled: September 23, 1997Date of Patent: July 20, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
-
Patent number: 5925736Abstract: The invention provides novel methods and compositions for the treatment of immune system-mediated arthritis, including rheumatoid arthritis. The subject compositions comprise one or more different types of collagen or collagen derivatives and a mucosa binding structure. Specific combinations of collagen and/or collagen derivatives may be used to treat specific types of arthritis. The collagen(s) and/or collagen(s) derivatives used in the subject compositions may be either obtained from natural sources or produced by recombinant genetic engineering techniques by chemical modification. Another aspect of the invention is to provide methods for treating various types of arthritis by administering an effective amount of the subject collagen-containing compositions. The methods of the invention involve the oral administration of a collagen or collagens found in a specific tissue, e.g.Type: GrantFiled: May 27, 1998Date of Patent: July 20, 1999Assignee: FibroGen, Inc.Inventors: Thomas Neff, George Martin, Karl A. Piez, Taina Pihlajaniemi, Kari I. Kivirikko
-
Patent number: 5922760Abstract: An agent for the prevention or alleviation of allergy symptoms contains as an effective component a dioxabycyclo?3.3.0!octane derivative represented by the following general formula (I): ##STR1## where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 each independently represent a hydrogen atom or alkyl group of 1-3 carbon atoms, or R.sup.1 and R.sup.2 and/or R.sup.4 and R.sup.5 together represent a methylene or ethylene group, and n, m and l represent 0 or 1.An agent for the prevention or alleviation of allergy symptoms also contains as an effective component an antioxidant in addition to the dioxabicyclo?3.3.0!octane derivative.Type: GrantFiled: June 19, 1997Date of Patent: July 13, 1999Assignee: Suntory LimitedInventors: Kengo Akimoto, Michihiro Sugano, Koji Yamada, Michiko Nonaka, Jiong-Yan Gu
-
Patent number: 5919754Abstract: The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.Type: GrantFiled: November 12, 1996Date of Patent: July 6, 1999Assignee: The Scripps Research InstituteInventors: Dario C. Altieri, Lucia R. Languino, George B. Thornton
-
Patent number: 5919460Abstract: The present invention is directed to a composition that can be used in alleviating symptoms associated with chronic fatigue syndrome or acquired immune deficiency syndrome. The composition is derived from the herbs Chimaphila umbellate, Apocynum andro-saemifolium, Symphytum officianale, and Equisetum hyemale. In addition, the invention is directed to a method of treating patients using this composition.Type: GrantFiled: January 28, 1998Date of Patent: July 6, 1999Inventor: Teresa J. Ingram
-
Patent number: 5917026Abstract: A DNA-sequence comprising a first sequence coding for a native or mutant subunit of a bacterial toxin that confers enzymatic ADP-ribosylating activity, and a second sequence coding for a peptide such that the resulting fusion protein is in possession of water solubility and capability of targeting the fusion protein to a specific cell receptor different from receptors binding to the native toxin, thereby mediating intracellular uptake of at least said subunit;fusion proteins coded for by such DNA-sequence;compositions for use in improving immune functions; andrecombinant expression vectors and transformed bacterial cells containing such DNA-sequence.Type: GrantFiled: February 5, 1996Date of Patent: June 29, 1999Inventors: Bjorn Lowenadler, Nils Lycke
-
Patent number: 5916564Abstract: The present invention involves the use of Tripterygium Wilfordii Hook F extracts in the treatment of rheumatoid arthritis. An alcohol extract of this plant (T2) inhibited antigen- and mitogen-stimulated proliferation of T cells and B cells, cell cycle progression, interleukin-2 (IL-2) production by T cells, immunoglobulin production by B cells and interleukin-2 mRNA production. T2 did not affect IL-2 receptor expression by T cells, IL-1 production by monocytes, the capacity of monocytes to present antigen, or signaling pathways. Inhibition could not be accounted for by nonspecific toxicity. These results support the conclusion that T2 exerts a powerful suppressive effect on human immune responses. Suppressing autoimmune disease is a most preferred embodiment of this invention.Type: GrantFiled: June 7, 1995Date of Patent: June 29, 1999Assignee: The University of Texas System--Board of RegentsInventors: Peter E. Lipsky, Xue-Lian Tao
-
Patent number: 5914331Abstract: A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or N.sup.4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.A process for the resolution of a racemic mixture of nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.Type: GrantFiled: June 7, 1995Date of Patent: June 22, 1999Assignee: Emory UniversityInventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
-
Patent number: 5912005Abstract: The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that encapsulates the living donor cell, wherein the uncoated particle provides a molecular weight cutoff that prevents host animal immune cells from entering the particle, yet does not have to prevent entry of host animal IgG and complement into the particle, and implanting the uncoated particle into the host animal.Type: GrantFiled: November 19, 1996Date of Patent: June 15, 1999Assignee: BioHybrid Technologies, Inc.Inventors: Robert P. Lanza, Willem M. Kuhtreiber, William L. Chick
-
Patent number: 5908845Abstract: A compound comprising a polyether backbone bearing a plurality of ligands that are individually bound to chiral carbon atoms located within said backbone, at least one of said ligands including a moiety selected from the group consisting of a naturally occurring nucleobase, a nucleobase binding group and a DNA intercalator; a process of synthesizing the compound, monomers to be used in this process and their synthesis process and processes for using the compound in biochemistry and medicine.Type: GrantFiled: October 30, 1996Date of Patent: June 1, 1999Inventor: David Segev
-
Patent number: 5906980Abstract: Abnormalities in the circulating immune complexes in a patient's blood, such as observed in patients having inflammatory disorders, viral infections, or simply deranged immune function, are restored to normal or viral immunity conferred by the administration of a matched or mismatched dsRNA.Type: GrantFiled: July 10, 1995Date of Patent: May 25, 1999Assignee: Hem Research Inc.Inventor: William A. Carter
-
Patent number: 5905071Abstract: The present invention relates to (2-aminoacylamino-2-deoxy-glycosyl)-amides, which are substituted on the nitrogen atom of the amino acid, of the general formula (I) ##STR1## in which the substituents have the meaning given in the description, to processes for their preparation and to their use in medicaments.Type: GrantFiled: June 25, 1996Date of Patent: May 18, 1999Assignee: Bayer AktiengesellschaftInventors: Oswald Lockhoff, Burkhard Mielke, Helmut Brunner, Klaus Schaller
-
Patent number: 5905068Abstract: A compound of the formula: ##STR1## is disclosed as a retroviral protease inhibitor compound. Also disclosed are methods and compositions for inhibiting an HIV infection.Type: GrantFiled: September 24, 1996Date of Patent: May 18, 1999Assignee: Abbott LaboratoriesInventors: Xiaoqi Chen, Brian E. Green, Dale J. Kempf, Lin Li, Daniel W. Norbeck, Hing L. Sham
-
Patent number: 5902786Abstract: The present invention discloses a method for treating patients having basal cell carcinoma comprising subcutaneous, intralesional or topical administration of Product R, a peptide-nucleic acid preparation.Type: GrantFiled: April 15, 1997Date of Patent: May 11, 1999Assignee: Advanced Viral Research Corp.Inventor: William Bregman
-
Patent number: 5902585Abstract: Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.Type: GrantFiled: August 5, 1997Date of Patent: May 11, 1999Assignees: University of Massachusetts Medical Center, The Trustees of Dartmouth CollegeInventors: Randolph J. Noelle, Fiona H. Durie, David C. Parker, Michael C. Appel, Nancy E. Phillips, John P. Mordes, Dale L. Grenier, Aldo A. Rossini
-
Patent number: 5902793Abstract: This invention is directed to a method for stimulating, the proliferation of V.gamma.2V.delta.2 T cells comprising contacting V.gamma.2V.delta.2 T cells with a V.gamma.2V.delta.2 T cell proliferation stimulating amount of a compound selected from the group-consisting of a monoalkyl phosphate, a hydroxy monoalkyl phosphate, a carboxy monoalkyl phosphate, a monoalkyl pyrophosphate, an alkenyl pyrophosphate, a .gamma.-monoalkyl nucleoside triphosphate, a .gamma.-monoalkyl deoxnucleoside triphosphate, a .gamma.-alkenyl nucleoside triphosphate, and a .gamma.-alkenyl deoxynucleoside triphosphate.Type: GrantFiled: June 16, 1997Date of Patent: May 11, 1999Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Barry R. Bloom, Yoshimasa Tanaka, Shigetoshi Sano
-
Patent number: 5900434Abstract: Process for the preparation of (-)-pimara-9(11),15-diene-19-oic acid(acanthoic acid) and pharmaceutical compositions comprising acanthoic acid useful for the treatment of diseases caused by an excessive production of interleukin-1 or tumor necrosis factor-.alpha..Type: GrantFiled: December 6, 1996Date of Patent: May 4, 1999Assignee: Korea Institute of Science and TechnologyInventors: Kwang-Ho Pyun, Inpyo Choi, Hyung-Sik Kang, Jung-Joon Lee, Young-Ho Kim
-
Patent number: 5891846Abstract: A stable emulsion composition containing cyclosporin, a polyalkyl ester of polycarboxylic acid in the form of liquid at ordinary temperature, an oil component having an I.O.B. of 0 to 0.25 in the form of a liquid at ordinary temperature, and a surfactant.Type: GrantFiled: February 19, 1998Date of Patent: April 6, 1999Assignee: Shiseido Company, Ltd.Inventors: Masami Ishida, Takashi Suzuki
-
Patent number: 5891841Abstract: The present invention relates to intercellular adhesion molecules (ICAM-3) which is involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes therapeutic and diagnostic uses for adhesion molecules and for the antibodies that are capable of binding them.Type: GrantFiled: June 7, 1995Date of Patent: April 6, 1999Assignee: The Center for Blood Research, Inc.Inventors: Antonin R. deFougerolles, Timothy A. Springer
-
Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
Patent number: 5888984Abstract: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.Type: GrantFiled: May 12, 1994Date of Patent: March 30, 1999Assignee: Dermal Research Laboratories, Inc.Inventor: Harold G. Brown -
Patent number: 5888552Abstract: This invention relates to a method of treatment of patients having lesions resulting from cancer cells and to an application as an anti-cancer composition of undenatured whey protein concentrate.Type: GrantFiled: May 8, 1995Date of Patent: March 30, 1999Assignee: Immunotec Research Corporation Ltd.Inventors: Gustavo Bounous, Phil Gold
-
Patent number: 5882674Abstract: A transdermal therapeutic system (TTS) comprises compounds releasing carbon monoxide in organisms to increase the CO-concentration in the organism.Type: GrantFiled: December 16, 1996Date of Patent: March 16, 1999Assignee: LTS Lohmann Therapie-Systeme GmbHInventors: Fritz Herrmann, Harald List
-
Patent number: 5876762Abstract: The invention concerns fractions from echinoderms of the class Holothuroidea (sea cucumber) that can be used directly as active therapeutic agents or as raw materials in producing biologically active derivatives thereof. The fractions can be used alone or in combination and are derived from a) the epithelial layer, free of muscle and collagenous tissues, b) the isolated flower, or c) the whole body wall substantially free muscle, viscera and flower. The invention also concerns processes for obtaining these fractions that involve the use of thermal/mechanical and/or enzymatic means.Type: GrantFiled: August 5, 1996Date of Patent: March 2, 1999Assignee: Coastside Bio ResourcesInventor: Peter Donald Collin
-
Patent number: 5874404Abstract: Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha.-chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha.-chain. The composition is clinically useful for blocking allergic responses. An animal model for use in the screening of prophylactic and therapeutic compositions for IgE-related diseases is also disclosed.Type: GrantFiled: May 3, 1994Date of Patent: February 23, 1999Assignees: Chisei Ra, The Green Cross CorporationInventors: Chisei Ra, Koji Naito, Minoru Hirama, Ko Okumura, Yukiyoshi Yanagihara
-
Patent number: 5872154Abstract: A method of reducing an immune response to a recombinant adenovirus which involves co-administration of the recombinant adenovirus and a selected immune modulator. The immune modulator functions by inhibiting the formation of neutralizing antibodies and/or reducing CTL killing of the virally infected cells. The method additionally encompasses the step of re-administering the recombinant adenovirus.Type: GrantFiled: February 24, 1995Date of Patent: February 16, 1999Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy & BiologyInventors: James M. Wilson, Yiping Yang, Giorgio Trinchieri
-
Patent number: 5871950Abstract: The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.Type: GrantFiled: June 5, 1995Date of Patent: February 16, 1999Inventors: Dinah S. Singer, Leonard Kohn, Edna Mozes, Motoyasu Saji, Jocelyn Weissman, Giorgio Napolitano, Fred D. Ledley
-
Patent number: 5871734Abstract: A method for the treatment of asthma is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a protein expressed on the surface of certain leukocytes such as eosinophils.Type: GrantFiled: March 21, 1997Date of Patent: February 16, 1999Assignee: Biogen, Inc.Inventors: Roy R. Lobb, Linda C. Burkly
-
Patent number: 5869090Abstract: Disclosed is a novel transdermal delivery system for dehydroepiandrosterone (DHEA). Using phospholipids as vehicles, DHEA can be administered into and through the skin when topically applied. Numerous advantages apply to this modality of therapy.Type: GrantFiled: January 20, 1998Date of Patent: February 9, 1999Inventor: Jerry Rosenbaum
-
Patent number: 5863528Abstract: A method of enhancing tolerance of a porcine transplant in a xenogeneic recipient by administering porcine bone marrow cells to the recipient and of enhancing proliferation and engraftment of the porcine bone marrow cells by exposing said cells to at least one substantially pure porcine cytokine and porcine cytokines that are substantially free of other porcine proteins and preferentially enhance the proliferation and engraftment of porcine bone marrow cells in the presence of bone marrow cells of other species. Protein and DNA sequence(s) for such porcine cytokines.Type: GrantFiled: May 26, 1995Date of Patent: January 26, 1999Assignee: BioTransplant, Inc.Inventors: Robert J. Hawley, Rodney L. Monroy, Margaret D. Rosa, Bernice Z. Schacter, Paul D. Pomath